BioSpace News Archive

Simplify Medical, Inc., maker of the Simplify® Cervical Artificial Disc, announced today the completion of the Pre-Market Approval (PMA) submission for the 2-level Simplify Disc IDE Study to the U.S. Food and Drug Administration (FDA

Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it will host a conference call and live audio webcast on November 5, 2020 at 4:30 p.m

Progression-Free Survival of 29.1 months reported in ROS1 TKI treatment-naïve patients and 14.1 months in patients pre-treated with one prior ROS1 TKI

Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that body composition data from the Company’s Phase III trial, DESTINY PWS (C601), evaluating once-daily Diazoxide Choline Controlled Release (DCCR) tablets for patients with Prader-Willi Syndrome (PWS),

Zogenix, Inc. (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it has changed the date of its previously announced earnings release and earnings call.

Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that it has scheduled its third quarter 2020 financial results and corporate update for Thursday, November 5, 2020

Expectations are increasing as a Korean bio-tech company has succeeded in solving the problem of low absorption which has been one of the biggest obstacles for the repositioning of Niclosamide, an anthelmintic, as the first orally ingested treatment for COVID-19.

CNS’ lead drug candidate Berubicin is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive form of brain cancer

- Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the Company”) today announces a 1-for-20 reverse share split of its outstanding ordinary shares. The reverse share split is scheduled to become effective after trading closes on October 29, 2020 , and the Company’s ordinary shares will begin trading on a split-adjusted basis on the Nasdaq C

Thermo Fisher and Symphogen continue work to support the development of innovative cancer treatments through optimization of protein characterization and quality monitoring mass spectrometry workflows